arrow
B

Byung-Wan Lee

yonsei university college of medicine
H指数:53
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trajectories of Albuminuria and Non-Albumin Proteinuria After Sequential Addition of Finerenone for Residual Albuminuria Despite Established SGLT2 Inhibitor Therapy in Diabetic Kidney Disease: A Real-World Cohort Study

在已使用SGLT2抑制剂治疗但仍有残余白蛋白尿的糖尿病肾病中,序贯加用非奈利酮后白蛋白尿和非白蛋白蛋白尿的轨迹:一项真实世界队列研究

2026-10-070
PRE
Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial

HD-6277(一种新型G蛋白偶联受体40激动剂)在2型糖尿病受试者中的疗效与安全性:一项双盲、随机、安慰剂对照、平行组、多中心Ⅱ期临床试验

2026-05-010
OA
Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial

在三联口服联合治疗控制不佳的2型糖尿病患者中,增加第四种口服降糖药与二甲双胍剂量递增的疗效和安全性 (努力): 一项为期24周的随机,开放标签,多中心试验

2026-02-030
PRE
Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
2025-11-010
OA
Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS-AP-combo and SURPASS-3

Tirzepatide治疗韩国2型糖尿病成人患者的有效性与安全性——SURPASS-AP-combo和SURPASS-3的后续分析

2025-09-150
OAAI
Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial

吡格列酮、恩格列净和格列美脲作为三线药物在用二甲双胍和DPP-4抑制剂控制不佳的2型糖尿病患者中的疗效与安全性:一项多中心、4期随机对照试验

2025-08-140
PREAI
Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial

噻唑烷二酮与钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病中治疗代谢功能障碍相关脂肪性肝病的协同效益:一项为期24周、开放标签、随机对照试验

2025-05-070
OA
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association

2型糖尿病中代谢功能障碍相关的脂肪变性肝病: 韩国糖尿病协会脂肪肝研究小组的回顾和立场声明

2024-11-300
PRE